| Description | TES-1025 is an effective and selective inhibitor of human α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (IC50: 13 nM). |
| In vitro | TES-1025 在细胞系统中提高NAD+水平[1]。 |
| In vivo | TES-1025 (0.5 mg/kg; i.v.) 表现出低血液清除率，具有较低的分布体积和约5.33小时的半衰期，尽管TES-1025 (5 mg/kg) 的血液浓度在口服后最多可检测到8小时。TES-1025 记录了良好的系统暴露，2小时时达到最大浓度Cmax 为2570 ng/mL。TES-1025 的口服暴露更大，其AUC0-8h 分别为19,200 h•ng/mL 和36,600 h•ng/mL[1]。 |
| Target activity | ACMSD (human):13±3 nM |
| molecular weight | 383.44 |
| Molecular formula | C18H13N3O3S2 |
| CAS | 1883602-21-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 95 mg/mL (247.76 mM), Sonication is recommended. |
| References | 1. Pellicciari R, et al. α-Amino-β-carboxymuconate-ε-semialdehyde Decarboxylase (ACMSD) Inhibitors as Novel Modulators of De Novo Nicotinamide Adenine Dinucleotide (NAD+) Biosynthesis. J Med Chem. 2018 Feb 8;61(3):745-759. |